IL13RA2
Interleukin-13 receptor subunit alpha-2
As of the edition of 20 October 2026, IL13RA2 (interleukin-13 receptor subunit alpha-2, UniProt Q14627) has 2 drugs tested at it and 1 company on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q14627
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- At a membrane
- Solved structures
- 1
- Disease areas
- Cancer; Nervous system; Hormones
- Registered trials of its drugs
- 12
Drugs at this target
| Status | Count |
|---|---|
| Stopped | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Cintredekin besudotox | Stopped | Phase 3 | none listed |
| IL-13-PE | Stopped | Phase 1 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Total on the list | 1 |
| Company | Route |
|---|---|
| INSYS Therapeutics | Route A |
The other 0 companies at IL13RA2
In the product1 company in all; 0 are not named here, and no score is.
See the 1 companies at IL13RA2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.